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Over the last decade, the availability of non-vitamin K antago-
nist oral anticoagulants (NOACs) has significantly changed the
daily clinical practice in managing thromboembolic risk in
patients with atrial fibrillation (AF).1 Guidelines for AF man-
agement have established that NOACs are the preferred treat-
ment for the majority of AF patients;2 however, recent data
from ‘real-life’ registries clearly show that a significant pro-
portion of patients are still treated with vitamin K antago-
nists.3–8 Nevertheless, the role of NOACs still seems to be
debated in some specific circumstances, such as their role in
the peri-operativemanagementof patientswithAF, in relation
to interruption or continuation of anticoagulation.
Themanagement of oral anticoagulation (OAC) therapy in
the peri-operative setting has been long debated. Despite the
absence of solid evidence, bridging OAC therapywith unfrac-
tioned heparin or low molecular weight heparin (LMWH)
was commonly suggested.9,10 In 2015, the ‘Bridging Antic-
oagulation in Patients who Require Temporary Interruption
of Warfarin Therapy for an Elective Invasive Procedure or
Surgery’ (BRIDGE) trial provided an answer to this important
issue regarding warfarin,11 demonstrating that while
patients undergoing bridging therapy with LMWH had a
similar risk for thromboembolic complications, they were at
significantly increased risk of major bleeding.11 Although
there has been some clarification about peri-procedural
management with warfarin, uncertainty still remains about
peri-procedural NOAC management, due to the lack of solid
data and limited clinical experience.
In the previous issue of Thrombosis and Haemostasis,
Douketis and colleagues presented a sub-group analysis on
peri-operative management and outcomes in AF patients
treated with warfarin or edoxaban, derived from the “Effec-
tive Anticoagulationwith Factor Xa Next Generation in Atrial
Fibrillation–Thrombolysis in Myocardial Infarction 48”
trial.12 Of the 21,105 patients originally enrolled in the trial,
7,193 (34.1%) required surgery or an invasive procedure, and
were equally randomized to warfarin, edoxaban high dose
(60 or 30 mg) and edoxaban low dose (30 or 15 mg), with no
major differences across the three groups. Themost common
procedures were cardiac, gastrointestinal endoscopy, dental
and electrophysiological. Among those undergoing elective
procedures, 3,116 (43.3%) had their anticoagulation inter-
rupted, defined as warfarin/edoxaban stopped for 4 to
10 days before the procedure, while 4,077 (56.7%) were
defined as ‘anticoagulant continued’, having stopped rando-
mized treatment  3 days (or not stopped at all) before the
procedure.12 A 30-day observation periodwas established to
determine if there were differences in efficacy and safety
betweenwarfarin and the two doses of edoxaban in patients
undergoing elective procedures, in patients with interrupted
or continued anticoagulation treatment.
In the anticoagulant interrupted group, rates of stroke or
systemic embolism at 30 days were 0.6, 0.5 and 0.9% for the
warfarin, edoxaban high dose and edoxaban low dose groups,
respectively (p ¼ 0.53 for differences across the groups). Cor-
responding figures in the anticoagulation-continued group
were 1.1, 0.7 and 0.9%, with no significant between-group
differences. Regarding the main safety outcome, major or
clinically relevant non-major (CRNM) bleeding was reported
in 3.9, 4.2 and 3.6% of patients receiving warfarin, edoxaban
high dose and edoxaban low dose, respectively, for the antic-
oagulation interrupted group, with no significant differences
across the three treatment groups. Among patients who
continued anticoagulation, rates of major/CRNM bleeding in
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the three treatment arms (p ¼ 0.17) were 8.5, 7.9 and 6.6%,
respectively. Mortality rates were similar across the three
treatments whether or not anticoagulation was interrupted
or continued.12 Results were comparable when analysed by
type of procedure.
These results, strengthened by the sample size and the
independently adjudicated outcomes, demonstrate that
edoxaban can be safely used andmanaged in patients under-
going elective procedures but that safety appears to be
improved if OAC is interrupted. These results, in particular
comparing NOACs and warfarin in major adverse outcomes,
reinforces and strengthens previous observations (►Table 1)
from sub-group analyses of other NOACs phase III trials, in
patients undergoing elective procedures.13–15
The current European Society of Cardiology AF guidelines
do not provide specific recommendations about themanage-
ment of OAC therapy in patients undergoing cardiovascular
procedures and interventions, but suggest that these inter-
ventions can be performed safely on continued OAC, and that
on the basis of the BRIDGE trial discussed previously, brid-
ging is not beneficial.2
More recently, the European Heart Rhythm Association
released a 2018 update to its practical guide on the use of
NOACs in AF patients, which discussed this issue in greater
detail,16 proposing peri-operative management of OAC ther-
apy as summarized in ►Fig. 1. The main points emphasized
by the practical guide relate to patients’ baseline character-
istics, in particular age and renal function, as well as the
theoretical bleeding risk carried by the specific procedure,
which needs to be taken into account when deciding whether
to stop NOACs or not. Second, given the predictable effect and
rapid clearance of NOACs, timely management of the planned
Table 1 Evidence about peri-procedural management of NOACs from phase III trials
Study Year NOAC Patients Procedures Treatments Results
Healey
et al13
2012 Dabigatran 4,591 (25.3%)  D110: 1,487
D150: 1,546
W: 1,558
Stroke/SE
D110 vs. W: RR, 1.05; 95% CI, 0.55–2.01
D150 vs. W: RR, 1.01; 95% CI, 0.35–2.87
Major Bleeding
D110 vs. W: RR, 0.83; 95% CI, 0.59–1.17
D150 vs. W: RR, 1.09; 95% CI, 0.80–1.49
Sherwood
et al14
2014 Rivaroxaban 4,692 (33.0%) 7,555 R: 2,165
W: 2,527
Stroke/SE
R vs. W: HR, 0.74; 95% CI, 0.36–1.50
Major Bleeding
R vs. W: HR, 1.26; 95% CI, 0.80–2.00
Garcia et al15 2014 Apixaban 5,439 (29.9%) 9,260 A: 2,701
W: 2,738
Stroke/SE
A vs. W: OR, 0.60; 95% CI, 0.32–1.12
Major Bleeding
A vs. W: OR, 0.85; 95% CI, 0.61–1.16
Abbreviations: A, apixaban; CI, confidence interval; D110, dabigatran 110 mg; D150, dabigatran 150 mg; HR, hazard ratio; NOAC, non-vitamin K
antagonist oral anticoagulant; OR, odds ratio; R, rivaroxaban; RR, relative risk; SE, systemic embolism; W, warfarin.
Fig. 1 Peri-operativemanagement forNOACs inAFpatients.OAC treatment canbecontinuedor restartedaccording tobleeding riskof theprocedure (solid
blocks). In specific situations,OACcanstopped later or restarted earlier if bleeding risk is consideredparticularly lowor theprocedure reportedan immediate
and complete haemostasis (striped blocks). Under physicians’ judgement, thromboprophylaxis with LMWH can be considered (dotted blocks). In patients
taking dabigatran, drug must be stopped as much earlier as lower is the renal function. Abbreviations: AF, atrial fibrillation; LMWH, low molecular weight
heparin; NOACs, non-vitamin K antagonist oral anticoagulants; OAC, oral anticoagulation.
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procedure can take advantage of the window between doses
administration.16
Taking these aspects into consideration, in procedures
with a minor bleeding risk (dental or eye procedures, diag-
nostic endoscopy and superficial surgery), all NOACs can be
continued safely up to the day before the procedure. No
NOACs are administered the morning of the procedure, and
in those cases performedwith no adverse events andwith an
immediate and complete haemostasis, NOACs can be
restarted at the subsequent programmed dose, but not until
6 hours post-procedure.16
In those procedures with a low bleeding risk (biopsies,
electrophysiological or procedures with cardiac implantable
devices, non-coronary angiographies), stop NOACs up to
24 hours before the procedure, and recommence based on
the same conditions as for minor bleeding risk procedures.16
For all those subjects undergoing procedureswith ahigh riskof
bleeding (complex endoscopies, major surgeries), the recom-
mendation is cessation of NOACs at least 48 hours before
surgery, without bridging. In these situations, NOACs can be
restarted 48 hours after the procedures (or longer in specific
situations) or post-procedure LMWH can be considered.16
In patients treated with dabigatran before the procedure,
it is recommended to perform an accurate evaluation of renal
function. In patients with a creatinine clearance (CrCl)
 80mL/min, dabigatran should be stopped 12 hours earlier
than in those with normal renal function (> 80mL/min);
24 hours earlier in patients with CrCl  50mL/min; and
36 hours earlier in patients  30mL/min. Similarly, in other
specific situations in which the NOACs clearance could be
prolonged, it is recommended to stop the treatment earlier.16
Another recent review about use of NOACs in surgical
scenarios, proposed similar recommendations, underlining
the importanceof stratifying theprocedure-predictedbleeding
risk and of knowing the expected clearance time of the specific
NOAC in the context of patient’s age and co-morbidities.17
Notwithstanding the results provided by the NOAC phase
III trials and expert recommendations, there is still a need
for more specific peri-operative data from adequately pow-
ered randomized studies to provide definitive evidence,
given the need to balance thromboembolic and bleeding
risks in AF management.18 To address this, the “Periopera-
tive Anticoagulant Use for Surgery Evaluation” study has
been initiated (ClinicalTrials.gov NCT02228798),19 a pro-
spective study with three parallel cohorts (dabigatran,
rivaroxaban and apixaban), aiming to enrol 3,291 patients
undergoing surgical procedures, to establish if the sug-
gested NOAC and patient-specific interruption–resumption
protocols are safe in the peri-operative management of AF
patients.19 Results from this study will provide stronger
evidence about the management of NOACs in this specific
setting.
Conclusion
Despite the availability of data from sub-group analyses of
the NOACs phase III trials and expert recommendations to
reassure clinicians about the efficacy and safety of NOACs in
the peri-operative management of AF patients (based on
their predictability of anticoagulation effect, rapid clearance
of effect), robust evidence from randomized controlled trials
is still required to further clarify the risks associated with
interruption or continuation of NOACs. Patient engagement,
education and counselling are additional practical aspects to
ensure safety while taking NOACs.20
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